Hepatocyte senescence in end‐stage chronic liver disease: a study of cyclin‐dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Histologic markers to predict hepatocellular carcinoma (HCC) include small cell change and dysplastic nodules. Hepatocyte senescence is noted in chronic liver disease and may or may not be important in progression to HCC. Aim: The study was undertaken to compare standard histologic features of chronic liver disease as well as markers of senescence and proliferation in two groups of biopsies from patients followed for at least a year. Methods: Standard histologic evaluation of necroinflammatory activity, fibrosis, steatosis, and iron, internationally accepted criteria of dysplasia, and immunohistochemical markers for proliferation and hepatocyte senescence were compared in 47 liver biopsies from noncholestatic chronic liver disease patients who subsequently either underwent transplant (the Control group, n=19) or had biopsy‐proven (HCC group, n=28) over a similar time period of 34.9 months (mean) and 42.5 months (mean) respectively. Results: Both groups were predominantly men; the MELD score was higher, and mean age was less in the Control group (46.9 vs 53.8 years, P=0.01). Small cell change was not significantly different in the biopsies between the two groups; neither were grade, stage (Ishak scores), nor presence or location of iron. Steatosis was more common in the group that subsequently developed HCC (P=0.04). The MIB‐1 proliferation index was greater in the biopsies from the Control group. The senescence marker p21, and the ratio of p21:MIB‐1 were not statistically different between the two groups. However, a Spearman's rank correlation showed a linear correlation of p21/MIB‐1 with a greater amount of dyplasia in the explant livers of Controls. Conclusions: These findings suggested the Control groups' livers maintained effective removal of cells from the cell cycle by overexpression of p21 and, while not ‘protected’ from significant involvement by dysplasia, may have been precluded from development of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis
WIEMANN, S. U., SATYANARAYANA, A., TSAHURIDU, M., TILLMANN, H. L., ZENDER, L., KLEMPNAUER, J., FLEMMING, P., FRANCO, S., BLASCO, M. A., MANNS, M. P., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0977com · Cited by 527
Clouston, A. D., Powell, E. E., Walsh, M. J., Richardson, M. M., Demetris, A. J., & Jonsson, J. R. (2005) · Hepatology · doi:10.1002/hep.20650 · Cited by 361
Cited by
Spahr, L., Chalandon, Y., Terraz, S., Kindler, V., Rubbia-Brandt, L., Frossard, J.-L., Breguet, R., Lanthier, N., Farina, A., Passweg, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053719 · Cited by 118
Cell senescence in liver diseases: pathological mechanism and theranostic opportunity
Sanfeliu-Redondo, D., Gibert-Ramos, A., & Gracia-Sancho, J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00913-4 · Cited by 117
“These senescent hepatocytes have been observed to be predominantly located in periportal or periseptal areas in human liver samples, in which more cell death and the subsequent regeneration occur 40,41 .”
Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration
Irvine, K. M., Skoien, R., Bokil, N. J., Melino, M., Thomas, G. P., Loo, D., Gabrielli, B., Hill, M. M., Sweet, M. J., Clouston, A. D., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17851 · Cited by 97
Large cell change of hepatocytes in chronic viral hepatitis represents a senescent-related lesion
Ikeda, H., Sasaki, M., Sato, Y., Harada, K., Zen, Y., Mitsui, T., & Nakanuma, Y. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.06.009 · Cited by 44
Metadata
- Authors
- Brunt, E. M., Walsh, S. N., Hayashi, P. H., LaBundy, J., & Di Bisceglie, A. M.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2007-04-05
- Volume
- 27
- Issue
- 5
- Pages
- 662-671
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2042142210
- Cited by
- 32
- References
- 2
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocyte senescence in end‐stage chronic liver disease: a study of cyclin‐dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. https://app.cochat.ai/papers/10.1111/j.1478-3231.2007.01470.x
- The paper
- Brunt, E. M., Walsh, S. N., Hayashi, P. H., LaBundy, J., & Di Bisceglie, A. M. (2007). Hepatocyte senescence in end‐stage chronic liver disease: a study of cyclin‐dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver International. https://doi.org/10.1111/j.1478-3231.2007.01470.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.